The Technical Analyst
OncoZenge AB (publ) [ONCOZ.ST]
Exchange: STO Sector: Healthcare Industry: Biotechnology
OncoZenge AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.13% SEK3.71
America/New_York / 17 mai 2024 @ 11:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 43.40 mill |
| EPS: | -1.360 |
| P/E: | -2.72 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 11.71 mill |
| Avg Daily Volume: | 0.0229 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.72 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -2.72 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK1.079 (-70.87%) SEK-2.63 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 3.27 - 4.15 ( +/- 11.97%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - SEK3.70
Forecast 2: 16:00 - SEK3.70
Forecast 3: 16:00 - SEK3.70
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK3.71 (-0.13% ) |
| Volume | 0.0106 mill |
| Avg. Vol. | 0.0229 mill |
| % of Avg. Vol | 46.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONCOZ.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONCOZ.ST
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).